Mazdutide
Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity
Innovent · Phase 3 · Recruiting · Enrollment 336
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| IBI362 treatment Group | n/r | n/r | n/r | n/r |
| Placebo Control Group | n/r | n/r | n/r | n/r |
Not shown
- IBI362 treatment Group: endpoint not reported
- Placebo Control Group: endpoint not reported